Paolo Bonini
CEO
Olobion
Biography
Paolo Bonini is founder and CEO of oloBion, a Spanish company specialized in advanced metabolomics, proteomics and lipidomics for the pharma, biotech, cosmetics and AgTech sectors. A scientist-entrepreneur with over 19 years of experience, Paolo has developed his career at the interface between plant science, analytical chemistry and innovation, contributing to several publications in journals such as Nature Biotechnology and Analytical Chemistry.
At oloBion, he leads a multidisciplinary team that translates complex omics data into actionable insights, helping cosmetic companies better understand skin biology, optimize formulations and accelerate innovation in efficacy, safety, personalization and regulatory compliance.
Conference
Day 1
Session 2: Exposome impact on Skin & Hair
Skin, Hair and Nails Exposome Through Omics
The exposome shapes skin, nails and hair biology through oxidative stress, barrier alteration, inflammation, and chemical accumulation.
oloBion analyzes skin, hair and nails with metabolomics and lipidomics to see how everyday exposures change them.
We standardize sampling: sebum swabs, stratum-corneum tape strips, and nail clippings and run both untargeted and targeted high-resolution mass-spectrometry assays. Rigorous QC with internal standards ensures reproducible lipidome and metabolome profiles including large population studies with inter-batch correction.
Our analyses detect more that 30 lipid classes like ceramide and free-fatty-acid remodeling; oxidized lipids and small-molecule markers of oxidative stress and inflammation; and retained xenobiotics and metabolites from food and drug exposure.
Across these three matrices we detected exogenous molecules acquired directly from external sources such as cosmetics (UV filters, e.g., octocrylene; fragrances/preservatives such as parabens), diet (capsaicin, resveratrol, caffeine), drugs and their metabolites, and environmental exposure (nicotine/cotinine, contaminants).
Data were compiled and processed in oloMAP, then subjected to bioinformatic and statistical analyses. We apply a multi-omic view, integrating metabolomics and lipidomics to test cross-layer interactions and shared pathways. Group comparisons (e.g., presence vs. absence; high vs. low) will reveal significant differences that support hypothesis generation, biomarker discovery, and translational applications, including objective endpoints and mode-of-action readouts for clinical or industry studies. Together, these results enable scalable exposome studies that bridge basic biology, product development, and clinical assessment.